Applying for a COVID-19 Emergency Use Authorization (EUA) Letter from FDA is no small feat, even though FDA has tried to simplify the process.
Applying for a COVID-19 Emergency Use Authorization (EUA) Letter from FDA is no small feat, even though FDA has tried to simplify the process to expedite the availability of diagnostic products, personal protective equipment (PPE), and therapeutics to handle the SARS-CoV-2 pandemic. (You can find FDA’s guidance here.) The upside is a less rigorous regulatory pathway and the ability to market your product prior to receiving full marketing approval. The downside is that the process itself is unfamiliar to most and has been modified more than once since initiation. Furthermore, there are a number of pitfalls or submission package deficiencies that can cause delays and/or rejection of the application.
Common pitfalls include inadequate testing procedures, failure to provide study protocols, presenting topline data only, and incomplete manufacturing data. Fortunately, many of these can be avoided by developing a complete submission package from the onset, rather than engaging in back and forth with FDA regarding deficiencies, which can be time-consuming and delay time to market. For instance, when submitting an EUA package for a serological diagnostic, FDA requires a minimum number of positive and negative samples tested for every matrix (i.e., whole blood, serum, plasma) that the product is intended for. Many applicants only test whole blood but request authorization to market and label the test for all matrices.
The EUA regulatory pathway is not intended as a permanent solution, but rather as a temporary process to address a critical need. Once the EUA process for a particular category expires, all EUAs will become defunct and EUA products removed from the market unless applications have been submitted via the standard (i.e., long and laborious) regulatory pathways. Let ISS assist you in taking advantage of the EUA process now.
ISS has assisted with the submission of dozens of EUA packages, and not just for coronavirus-specific drugs, diagnostics, and devices. We’ve worked directly with FDA on behalf of our clients (as authorized US agents) in order to address deficiencies or revise submissions based on evolving requirements. We know this process inside and out.
Complete the form below to download our free white paper “Applying for an FDA Coronavirus EUA Letter” or contact us today to discuss how we can help.
We have summarized our extensive experience into this easy-to-read, practical guide.
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us